GNMX Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| GNMX | -3.1% | +10.8% | — | — | — | — |
| Equity average (4725 funds) | -2.2% | -4.7% | +3008.3% | +1886.0% | +15.1% | +2.6% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: −$4K net.
Holdings · as of Nov 13, 2026
| # | Holding | Weight |
|---|---|---|
| 1 | MRNA Moderna Inc | 10.86% |
| 2 | TMO Thermo Fisher Scientific Inc | 9.49% |
| 3 | VRTX Vertex Pharmaceuticals Inc | 6.45% |
| 4 | GMAB Genmab A/S | 4.45% |
| 5 | ILMN Illumina Inc | 3.91% |
| 6 | GH Guardant Health Inc | 3.42% |
| 7 | RVMD Revolution Medicines Inc | 3.09% |
| 8 | INCY Incyte Corp | 2.89% |
| 9 | TXG 10X Genomics Inc | 2.71% |
| 10 | GNMX First American Government Obligations Fund 12/01/2031 | 2.66% |
| 11 | CDNA CareDx Inc | 2.44% |
| 12 | TECH Bio-Techne Corp | 2.26% |
| 13 | QGEN QIAGEN NV | 2.21% |
| 14 | GRAL GRAIL Inc | 2.06% |
| 15 | BMRN BioMarin Pharmaceutical Inc | 2.02% |
| 16 | TEM Tempus AI Inc | 2.02% |
| 17 | TWST Twist Bioscience Corp | 2.00% |
| 18 | ADPT Adaptive Biotechnologies Corp | 1.97% |
| 19 | ALNY Alnylam Pharmaceuticals Inc | 1.77% |
| 20 | IOVA Iovance Biotherapeutics Inc | 1.76% |
| 21 | KRYS Krystal Biotech Inc | 1.73% |
| 22 | SDGR Schrodinger Inc/United States | 1.59% |
| 23 | NEO NeoGenomics Inc | 1.37% |
| 24 | PSNL Personalis Inc | 1.27% |
| 25 | CRSP CRISPR Therapeutics AG | 1.13% |
| 26 | ABSI Absci Corp | 1.12% |
| 27 | BRKS Azenta Inc | 1.12% |
| 28 | CERT Certara Inc | 1.11% |
| 29 | IDYA Ideaya Biosciences Inc | 1.10% |
| 30 | ARWR Arrowhead Pharmaceuticals Inc | 1.09% |
| 31 | CAI Caris Life Sciences Inc | 1.08% |
| 32 | RLAY Relay Therapeutics Inc | 1.03% |
| 33 | QURE uniQure NV | 0.95% |
| 34 | BEAM Beam Therapeutics Inc | 0.87% |
| 35 | CSTL Castle Biosciences Inc | 0.82% |
| 36 | RXRX Recursion Pharmaceuticals Inc | 0.80% |
| 37 | NRIX Nurix Therapeutics Inc | 0.79% |
| 38 | SRPT Sarepta Therapeutics Inc | 0.76% |
| 39 | IONS Ionis Pharmaceuticals Inc | 0.74% |
| 40 | VCYT Veracyte Inc | 0.74% |
| 41 | FLGT Fulgent Genetics Inc | 0.66% |
| 42 | FDMT 4D Molecular Therapeutics Inc | 0.65% |
| 43 | NTLA Intellia Therapeutics Inc | 0.64% |
| 44 | SOPH Sophia Genetics SA | 0.63% |
| 45 | RARE Ultragenyx Pharmaceutical Inc | 0.63% |
| 46 | GENB Generate Biomedicines Inc | 0.60% |
| 47 | PACB Pacific Biosciences of California Inc | 0.59% |
| 48 | WGS GeneDx Holdings Corp | 0.59% |
| 49 | MYGN Myriad Genetics Inc | 0.56% |
| 50 | SLDB Solid Biosciences Inc | 0.50% |
| 51 | PRME Prime Medicine Inc | 0.48% |
| 52 | ARCT Arcturus Therapeutics Holdings Inc | 0.34% |
| 53 | DTIL Precision BioSciences Inc | 0.34% |
| 54 | RCKT Rocket Pharmaceuticals Inc | 0.29% |
| 55 | FLDM STANDARD BIOTOOLS INC | 0.29% |
| 56 | EDIT Editas Medicine Inc | 0.28% |
| 57 | BDSX Biodesix Inc | 0.23% |
| 58 | CRBU Caribou Biosciences Inc | 0.06% |
Sector breakdown
Country breakdown
Distributions
No distributions on file.
Members of Congress who disclosed this ETF
No member of Congress has disclosed a trade in GNMX in the filings we hold.
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error